Page last updated: 2024-11-02

pirenzepine and Psychotic Disorders

pirenzepine has been researched along with Psychotic Disorders in 192 studies

Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.

Psychotic Disorders: Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)

Research Excerpts

ExcerptRelevanceReference
"The subjects were 45 inpatients with DSM-IV schizophrenia or schizoaffective disorder who failed to respond to treatment during a 14-week double-blind trial comparing clozapine, olanzapine, risperidone, and haloperidol."9.10Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. ( Chakos, M; Citrome, L; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002)
"A multicenter, randomized, international, 2-year study comparing the risk for suicidal behavior in patients treated with clozapine vs olanzapine was conducted in 980 patients with schizophrenia or schizoaffective disorder, 26."9.10Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). ( Alphs, L; Altamura, AC; Anand, R; Bertoldi, A; Bourgeois, M; Chouinard, G; Green, AI; Islam, MZ; Kane, J; Krishnan, R; Lindenmayer, JP; Meltzer, HY; Potkin, S, 2003)
"The aim of the present study was to evaluate the objective and subjective efficacy as well as tolerability of olanzapine in acute treatment of schizophrenia spectrum disorders under naturalistic non-selective conditions."9.10Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders. ( Holzbach, R; Krausz, M; Lambert, M; Moritz, S; Naber, D; Postel, N, 2003)
"To examine the effects of risperidone and olanzapine on cognitive functioning in elderly patients with schizophrenia or schizoaffective disorder."9.10Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. ( Gharabawi, G; Harvey, PD; Mao, L; Napolitano, JA, 2003)
"To determine whether patients with treatment-resistant schizophrenia or schizoaffective disorder would respond when switched to olanzapine and whether they could maintain their response on this atypical antipsychotic."9.10Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up. ( Karagianis, JL; LeDrew, KK; Walker, DJ, 2003)
"To compare the effects of risperidone and olanzapine on cognition in elderly patients with dementia and psychosis, and to compare the side effects of these drugs."9.10Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis. ( Arndt, S; Ekstam-Smith, K; Ellingrod, VL; Kutscher, E; Schultz, SK; Turvey, C, 2002)
"The authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder."9.10Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002)
"4 years) with DSM-IV schizophrenia or related disorders (N = 113) who were treated with olanzapine or risperidone."9.10Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. ( Beuk, N; de Haan, L; Dingemans, P; Hoogenboom, B; Linszen, D, 2002)
"Newer antipsychotic drugs have shown promise in ameliorating neurocognitive deficits in patients with schizophrenia, but few studies have compared newer antipsychotic drugs with both clozapine and conventional agents, particularly in patients who have had suboptimal response to prior treatments."9.10Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. ( Bilder, RM; Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Goldman, RS; Hoptman, M; Horowitz, TL; Kunz, M; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2002)
"Olanzapine's structural similarities to clozapine and the results of premarketing clinical trials suggested potential usefulness in treating patients with treatment-refractory psychoses."9.09An open trial of olanzapine in patients with treatment-refractory psychoses. ( Mossman, D; Sanders, RD, 1999)
"Weight change and the weight-related health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in patients with DSM-III-R schizophrenia and related disorders who received treatment with olanzapine for up to 3 years, and comparisons were made to patients treated with haloperidol."9.09Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. ( Basson, BR; Gilmore, JA; Kinon, BJ; Tollefson, GD, 2001)
" Amantadine (100-300 mg/day) was started in 12 patients having a mean weight gain of 7."9.09Effect of amantadine on weight gain during olanzapine treatment. ( Deberdt, W; Floris, M; Lejeune, J, 2001)
"Subjects (N=377) who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomly assigned to receive 2-6 mg/day of risperidone (mean modal dose=4."9.09A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. ( Conley, RR; Mahmoud, R, 2001)
"A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive clozapine, olanzapine, risperidone, or haloperidol in a double-blind 14-week trial."9.09Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2001)
"To determine the clinical effects and safety of olanzapine as compared with placebo, typical and other atypical antipsychotic drugs for schizophrenia and schizophreniform psychoses."8.82Olanzapine for schizophrenia. ( Dardennes, RM; Duggan, L; El-Dosoky, A; Fenton, M; Indran, S, 2003)
"The frequency of neuroleptic malignant syndrome (NMS) after clozapine or olanzapine is low and often of non-serious nature."8.82[Life threatening neuroleptic malignant syndrome due to olanzapine]. ( Becker, T; Kopf, A; Köster, J; Krömker, H; Schulz, A, 2003)
"To evaluate the efficacy and safety of olanzapine for the treatment of psychotic and behavioral disturbances in Alzheimer disease."8.82Olanzapine for psychotic and behavioral disturbances in Alzheimer disease. ( Schatz, RA, 2003)
"To determine the clinical effects and safety of olanzapine as compared with placebo, typical and other atypical antipsychotic drugs for schizophrenia and schizophreniform psychoses."8.80Olanzapine for schizophrenia. ( Dardennes, RM; Duggan, L; El-Dosoky, A; Fenton, M; Indran, S, 2000)
"Olanzapine is a thienobenzodiazepine derivative which displays efficacy in patients with schizophrenia and related psychoses."8.79Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. ( Fulton, B; Goa, KL, 1997)
"The increasing use of olanzapine for treating adolescent patients has brought with it greater awareness of the recognized side effects of this medication, especially weight gain."7.72Hyperglycemia from olanzapine treatment in adolescents. ( Bloch, Y; Gothelf, D; Levkovitz, Y; Mendlovic, S; Ratzoni, G; Vardi, O, 2003)
"These data demonstrate that, in older patients with schizophrenia and related psychotic disorders, risperidone and olanzapine have approximately equal efficacy in controlling positive symptoms."7.72Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. ( Breier, A; Feldman, PD; Kaiser, CJ; Kennedy, JS; Sutton, VK; Tollefson, GD; Tran, PV; Zhang, F, 2003)
" We report a 48 years old male drinker and addicted to cocaine, that after two months of Olanzapine use, developed a severe diabetes mellitus with fasting blood glucose values reaching 514 mg/dl."7.71[Diabetes mellitus induced by olanzapine. A case report]. ( Arancibia, P; Bravo, V; Rojas, P; Varela, S, 2001)
"Three studies compared olanzapine and haloperidol given orally in maintenance therapy for schizophrenia and related psychoses."7.70Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. ( Beasley, CM; Dellva, MA; Tollefson, GD; Tran, PV; Wentley, AL, 1998)
"The aim of the present paper is to report a case of Neuroleptic Malignant Syndrome (NMS) occurring 2 days after olanzapine was added to the treatment regimen of an elderly patient with Schizoaffective Disorder."7.70Neuroleptic malignant syndrome associated with olanzapine. ( Bruxner, G; Johnson, V, 1998)
"Fourteen patients on treatment with olanzapine (all meeting DSM-IV criteria for schizophrenia or related psychoses) were studied."7.70Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. ( Brismar, KE; Hulting, AL; Melkersson, KI, 2000)
"Olanzapine is a novel antipsychotic effective in reducing positive and negative symptoms of schizophrenia and with a safe side-effect profile."6.69Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. ( Brenner, R; Concepcion, NM; Florita, CD; Kaur, A; Madhusoodanan, S; Menon, G; Nunez, G; Reddy, H; Suresh, P, 2000)
" The manuscript describes the pharmacology, efficacy and tolerability studies, adverse effects and dosing considerations in the elderly."6.41Use of olanzapine for elderly patients with psychotic disorders: a review. ( Bogunovic, O; Brenner, R; Gupta, S; Madhusoodanan, S; Sinha, S, 2001)
"Twenty-one patients with Parkinson's disease and psychosis were included in an open-label 8-week trial of olanzapine."5.30Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. ( Aarsland, D; Larsen, JP; Lim, NG; Tandberg, E, 1999)
"In a prospective, single-blinded, naturalistic study, a cohort of subjects (n=150) with schizophrenia or schizo-affective disorder (DSM-IV) were switched from conventional neuroleptic drugs to either risperidone (n=50), olanzepine (n=50) or quetiapine (n=50), and monitored for a period of 2 to 6 years."5.10Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. ( Awad, A; Cernovsky, Z; Cortese, L; Kotteda, V; Owyeumi, L; Voruganti, L; Zirul, S, 2002)
"The subjects were 45 inpatients with DSM-IV schizophrenia or schizoaffective disorder who failed to respond to treatment during a 14-week double-blind trial comparing clozapine, olanzapine, risperidone, and haloperidol."5.10Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. ( Chakos, M; Citrome, L; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002)
"A multicenter, randomized, international, 2-year study comparing the risk for suicidal behavior in patients treated with clozapine vs olanzapine was conducted in 980 patients with schizophrenia or schizoaffective disorder, 26."5.10Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). ( Alphs, L; Altamura, AC; Anand, R; Bertoldi, A; Bourgeois, M; Chouinard, G; Green, AI; Islam, MZ; Kane, J; Krishnan, R; Lindenmayer, JP; Meltzer, HY; Potkin, S, 2003)
" The authors' goal was to assess the effects of clozapine, olanzapine, risperidone, and haloperidol on glucose and cholesterol levels in hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blind 14-week trial."5.10Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2003)
"The aim of the present study was to evaluate the objective and subjective efficacy as well as tolerability of olanzapine in acute treatment of schizophrenia spectrum disorders under naturalistic non-selective conditions."5.10Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders. ( Holzbach, R; Krausz, M; Lambert, M; Moritz, S; Naber, D; Postel, N, 2003)
"To examine the effects of risperidone and olanzapine on cognitive functioning in elderly patients with schizophrenia or schizoaffective disorder."5.10Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. ( Gharabawi, G; Harvey, PD; Mao, L; Napolitano, JA, 2003)
"To determine whether patients with treatment-resistant schizophrenia or schizoaffective disorder would respond when switched to olanzapine and whether they could maintain their response on this atypical antipsychotic."5.10Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up. ( Karagianis, JL; LeDrew, KK; Walker, DJ, 2003)
"To compare the effects of risperidone and olanzapine on cognition in elderly patients with dementia and psychosis, and to compare the side effects of these drugs."5.10Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis. ( Arndt, S; Ekstam-Smith, K; Ellingrod, VL; Kutscher, E; Schultz, SK; Turvey, C, 2002)
"The authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder."5.10Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002)
"4 years) with DSM-IV schizophrenia or related disorders (N = 113) who were treated with olanzapine or risperidone."5.10Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. ( Beuk, N; de Haan, L; Dingemans, P; Hoogenboom, B; Linszen, D, 2002)
"Newer antipsychotic drugs have shown promise in ameliorating neurocognitive deficits in patients with schizophrenia, but few studies have compared newer antipsychotic drugs with both clozapine and conventional agents, particularly in patients who have had suboptimal response to prior treatments."5.10Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. ( Bilder, RM; Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Goldman, RS; Hoptman, M; Horowitz, TL; Kunz, M; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2002)
"Olanzapine's structural similarities to clozapine and the results of premarketing clinical trials suggested potential usefulness in treating patients with treatment-refractory psychoses."5.09An open trial of olanzapine in patients with treatment-refractory psychoses. ( Mossman, D; Sanders, RD, 1999)
"Two hundred nine outpatients with a DSM-IV diagnosis of schizophrenia or schizo-affective disorder who were clinically stable while being treated with a conventional antipsychotic drug or risperidone were openly randomly assigned to either abrupt or gradual discontinuation of their prior antipsychotic drug."5.09Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. ( Basson, BR; Gilmore, JA; Kinon, BJ; Malcolm, S; Stauffer, VL, 2000)
"Clozapine is an atypical antipsychotic indicated for the management of severely ill patients with schizophrenia who have failed to respond adequately to standard drug treatment."5.09Switching clozapine responders to olanzapine. ( Hilligoss, NM; Johnson, CG; Littrell, KH; Littrell, SH; Peabody, CD, 2000)
" This article compares the effects of olanzapine and placebo in the emergence of hallucinations or delusions in AD patients with symptoms of agitation/aggression but little or no psychotic symptomatology at baseline."5.09The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. ( Breier, A; Clark, WS; Feldman, PD; Street, JS, 2001)
"Weight change and the weight-related health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in patients with DSM-III-R schizophrenia and related disorders who received treatment with olanzapine for up to 3 years, and comparisons were made to patients treated with haloperidol."5.09Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. ( Basson, BR; Gilmore, JA; Kinon, BJ; Tollefson, GD, 2001)
" Amantadine (100-300 mg/day) was started in 12 patients having a mean weight gain of 7."5.09Effect of amantadine on weight gain during olanzapine treatment. ( Deberdt, W; Floris, M; Lejeune, J, 2001)
"Subjects (N=377) who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomly assigned to receive 2-6 mg/day of risperidone (mean modal dose=4."5.09A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. ( Conley, RR; Mahmoud, R, 2001)
", who received at least 6 weeks of add-on olanzapine treatment for psychotic mood disorders (schizoaffective disorders [bipolar and depressive type], bipolar disorders [I, II, and NOS], and major depressive disorder)."5.09Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study. ( Grace, JJ; Narendran, R; Pato, MT; Pristach, CA; Valenti, AM; Young, CM, 2001)
"A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive clozapine, olanzapine, risperidone, or haloperidol in a double-blind 14-week trial."5.09Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2001)
"Data were analyzed from three actively controlled and blind long-term responder studies of subjects meeting DSM-III-R criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder treated with olanzapine (N = 707, up to 20 mg/day, 237 median days of exposure) or haloperidol (N = 197, up to 20 mg/day, 203 median days of exposure) who did not have evidence of tardive dyskinesia at baseline."5.08Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. ( Beasley, CM; Potvin, JH; Tamura, RN; Tollefson, GD; Tran, PV, 1997)
"To determine the clinical effects and safety of olanzapine as compared with placebo, typical and other atypical antipsychotic drugs for schizophrenia and schizophreniform psychoses."4.82Olanzapine for schizophrenia. ( Dardennes, RM; Duggan, L; El-Dosoky, A; Fenton, M; Indran, S, 2003)
"The frequency of neuroleptic malignant syndrome (NMS) after clozapine or olanzapine is low and often of non-serious nature."4.82[Life threatening neuroleptic malignant syndrome due to olanzapine]. ( Becker, T; Kopf, A; Köster, J; Krömker, H; Schulz, A, 2003)
"To evaluate the efficacy and safety of olanzapine for the treatment of psychotic and behavioral disturbances in Alzheimer disease."4.82Olanzapine for psychotic and behavioral disturbances in Alzheimer disease. ( Schatz, RA, 2003)
" The present article reviews important differences among antipsychotic drugs in the potential for, and occurrence of, serious adverse cardiac outcomes and suggests that olanzapine, as therapeutically administered to patients with schizophrenia and related psychoses, does not contribute significantly to a QTc prolongation that could result in potentially fatal ventricular arrhythmias."4.81Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. ( Beasley, CM; Czekalla, J; Kollack-Walker, S, 2001)
"A computerized search, using the MEDLINE database (1966-summer 2000), located cases of priapism associated with most conventional antipsychotics as well as with clozapine, risperidone, and olanzapine."4.81Priapism associated with conventional and atypical antipsychotic medications: a review. ( Compton, MT; Miller, AH, 2001)
"To determine the clinical effects and safety of olanzapine as compared with placebo, typical and other atypical antipsychotic drugs for schizophrenia and schizophreniform psychoses."4.80Olanzapine for schizophrenia. ( Dardennes, RM; Duggan, L; El-Dosoky, A; Fenton, M; Indran, S, 2000)
" Compared with risperidone, olanzapine causes greater increases in weight gain and body mass index but less hyperprolactinemia."4.80Adverse events related to olanzapine. ( Conley, RR; Meltzer, HY, 2000)
"Olanzapine is a thienobenzodiazepine derivative which displays efficacy in patients with schizophrenia and related psychoses."4.79Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. ( Fulton, B; Goa, KL, 1997)
" This article will describe the potential use of the atypical antipsychotics, especially olanzapine, for affective mood disturbances in schizophrenia, psychotic depression and mania, first-break schizophrenia, comorbid schizophrenia and substance abuse disorders, dementia in the elderly and those with late-onset schizophrenia, and behavioral problems in patients with mental retardation or developmental delays."4.79Olanzapine and the new generation of antipsychotic agents: patterns of use. ( Glazer, WM, 1997)
"The unprecedented level of activity in the development of new antipsychotic medications can be traced to the 1989 approval of clozapine by the US Food and Drug Administration for treatment of refractory schizophrenia."4.79New antipsychotic medications: strategies for evaluation and selected findings. ( Schooler, NR, 1997)
" Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS-UK) program consisted of a retrospective review of medical notes and prescription charts for 501 patients with schizophrenia or schizoaffective disorder who had been admitted to the hospital for the treatment of psychosis."3.72Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. ( Libretto, SE; Taylor, DM; Wright, T, 2003)
"The increasing use of olanzapine for treating adolescent patients has brought with it greater awareness of the recognized side effects of this medication, especially weight gain."3.72Hyperglycemia from olanzapine treatment in adolescents. ( Bloch, Y; Gothelf, D; Levkovitz, Y; Mendlovic, S; Ratzoni, G; Vardi, O, 2003)
"These data demonstrate that, in older patients with schizophrenia and related psychotic disorders, risperidone and olanzapine have approximately equal efficacy in controlling positive symptoms."3.72Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. ( Breier, A; Feldman, PD; Kaiser, CJ; Kennedy, JS; Sutton, VK; Tollefson, GD; Tran, PV; Zhang, F, 2003)
"Ten of 20 stable patients with schizophrenia or schizoaffective disorder who were treated with olanzapine for at least 4 weeks had the opportunity to receive access to a Young Men's Christian Association (YMCA) fitness facility, based on random allocation."3.72Pilot study: access to fitness facility and exercise levels in olanzapine-treated patients. ( Archie, S; Hobbs, H; McNiven, J; Osborne, S; Wilson, JH, 2003)
"Twenty-four patients taking daily doses of olanzapine of 20, 25, 30, and 40 mg for DSM-IV schizophrenia or schizoaffective disorder had serum prolactin levels measured."3.72High-dose olanzapine and prolactin levels. ( Baksh, A; Karagianis, JL, 2003)
"Patients with a Diagnostic and Statistical Manual of Mental Disorders (third edition, revised) diagnosis of schizophrenia or psychotic disorder not otherwise specified with onset of psychosis before the age of 13 participated in 6- to 8-week open or double-blind trials of haloperidol (n = 15, mean dose 15."3.71Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. ( Alfaro, CL; Gochman, P; Lenane, M; Nicolson, R; Rapoport, JL; Sporn, A; Wudarsky, M, 2002)
" However, accumulating evidence suggests that these agents, particularly clozapine and olanzapine, have serious side effects of their own, including weight gain and elevated glucose and triglyceride levels."3.71The effects of novel antipsychotics on glucose and lipid levels. ( Ballon, JS; Boyd, JA; Marder, SR; Meng, LR; Wirshing, DA; Wirshing, WC, 2002)
" We report a 48 years old male drinker and addicted to cocaine, that after two months of Olanzapine use, developed a severe diabetes mellitus with fasting blood glucose values reaching 514 mg/dl."3.71[Diabetes mellitus induced by olanzapine. A case report]. ( Arancibia, P; Bravo, V; Rojas, P; Varela, S, 2001)
"The aim of this study was to evaluate the mechanisms underlying weight gain induced by the atypical antipsychotic, olanzapine."3.71Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study. ( Franssila-Kallunki, A; Naukkarinen, H; Rissanen, A; Virkkunen, M; Wahlbeck, K, 2002)
"Three studies compared olanzapine and haloperidol given orally in maintenance therapy for schizophrenia and related psychoses."3.70Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. ( Beasley, CM; Dellva, MA; Tollefson, GD; Tran, PV; Wentley, AL, 1998)
"The aim of the present paper is to report a case of Neuroleptic Malignant Syndrome (NMS) occurring 2 days after olanzapine was added to the treatment regimen of an elderly patient with Schizoaffective Disorder."3.70Neuroleptic malignant syndrome associated with olanzapine. ( Bruxner, G; Johnson, V, 1998)
"Fourteen patients on treatment with olanzapine (all meeting DSM-IV criteria for schizophrenia or related psychoses) were studied."3.70Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. ( Brismar, KE; Hulting, AL; Melkersson, KI, 2000)
" Olanzapine is one of the atypical antipsychotics with efficacy for psychotic symptoms and a safer side-effect profile than typical antipsychotics."2.71The efficacy and safety of olanzapine for the treatment of geriatric psychosis. ( Hwang, JP; Lee, TW; Tsai, SJ; Yang, CH, 2003)
"Olanzapine-treated patients experienced a lower rate of treatment-emergent parkinsonism and akathisia but had significantly more weight gain, compared with the haloperidol-treated patients."2.71Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. ( Green, AI; Gur, RE; Hamer, RM; Kahn, R; Lieberman, JA; McEvoy, J; Perkins, D; Sharma, T; Tohen, M; Tollefson, G; Wei, H; Zipursky, R, 2003)
"Historical predictors were diagnosis of schizoaffective disorder, history or current use at baseline of alcohol or substance abuse, cigarette smoking, number of lifetime suicide attempts, and the number of hospitalizations in the previous 36 months to prevent suicide."2.71Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial. ( Alphs, L; Anand, R; Green, A; Hsu, C; Krishnan, KR; Meltzer, H; Potkin, SG; Young, FK, 2003)
" The treating clinician was free to vary or discontinue dosing and use additional medications."2.71A 1-year open-label trial of olanzapine in school-age children with schizophrenia. ( Adler, LE; Farley, GK; Novins, D; Ross, RG, 2003)
"Psychosis was assessed with the Neuropsychiatric Inventory/Nursing Home (NPI-NH) version and the Brief Psychiatric Rating Scale (BPRS)."2.70Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. ( Clark, WS; Cummings, JL; Masterman, D; Street, J, 2002)
"Patients with schizoaffective disorder bipolar type, characterized as currently manic, mixed, depressed, or euthymic, were assessed weekly for 6 weeks during treatment with either olanzapine or haloperidol."2.70Olanzapine versus haloperidol in schizoaffective disorder, bipolar type. ( Breier, A; Feldman, PD; Keck, PE; Risser, RC; Tohen, M; Tran, PV; Zhang, F, 2001)
"Olanzapine is a recently introduced atypical neuroleptic agent for which little information is available on its use in children."2.69Open-label olanzapine treatment in five preadolescent children. ( King, BH; Krishnamoorthy, J, 1998)
"Haloperidol-treated first-episode patients experienced statistically significantly more extrapyramidal symptoms than haloperidol-treated multiple-episode patients."2.69Olanzapine versus haloperidol treatment in first-episode psychosis. ( Beasley, C; Grundy, S; Lieberman, JA; Sanger, TM; Tohen, M; Tollefson, GD, 1999)
"Olanzapine-treated patients achieved a statistically significant greater improvement than haloperidol treated patients on overall measures of efficacy, including clinical response."2.69Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy. ( Beasley, CM; Berg, PH; Lu, Y; Sanger, TM; Tollefson, GD; Tran, PV, 1999)
"Psychosis is a defining feature of schizophrenia consisting of formal thought disorder, delusions, and hallucinations."2.69The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome. ( Berg, PH; Breier, A, 1999)
"Olanzapine is a novel antipsychotic effective in reducing positive and negative symptoms of schizophrenia and with a safe side-effect profile."2.69Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. ( Brenner, R; Concepcion, NM; Florita, CD; Kaur, A; Madhusoodanan, S; Menon, G; Nunez, G; Reddy, H; Suresh, P, 2000)
"Olanzapine-treated patients had serum anticholinergic levels that were less than one fifth those of the clozapine-treated patients."2.69Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. ( Brar, JS; Chengappa, KN; Kirshner, MA; Levine, J; Parepally, H; Pollock, BG; Zoretich, RA, 2000)
" The D2 receptor availability revealed an exponential dose-response relationship (r = - 0."2.69D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study. ( Dresel, S; Frodl, T; Hahn, K; Mager, T; Meisenzahl, EM; Möller, HJ; Preuss, UW; Rossmüller, B; Schmitt, GJ; Tatsch, K, 2000)
"However, diagnosis of schizoaffective disorder is included both in DSM-IV-TR and ICD-10."2.41[Schizoaffective disorder: clinical symptoms and present-day approach to treatment]. ( Danileviciūte, V, 2002)
" The manuscript describes the pharmacology, efficacy and tolerability studies, adverse effects and dosing considerations in the elderly."2.41Use of olanzapine for elderly patients with psychotic disorders: a review. ( Bogunovic, O; Brenner, R; Gupta, S; Madhusoodanan, S; Sinha, S, 2001)
"Risperidone appears to be an effective therapy, but several authors report cases of TD during treatment."2.41Tardive dyskinesias and antipsychotics: a review. ( Bayle, FJ; Chereau, I; Lancon, C; Llorca, PM, 2002)
" Dosing requirements for elderly patients tend to be much lower than those for younger adults."2.40Conventional vs. newer antipsychotics in elderly patients. ( Harris, MJ; Jeste, DV; Lacro, J; Lohr, JB; Rockwell, E, 1999)
"Olanzapine is a novel antipsychotic agent displaying a unique and pleotrophic pharmacology, which distinguishes it from other existing treatments."2.40Review of recent clinical studies with olanzapine. ( Kuntz, AJ; Tollefson, GD, 1999)
"The psychotic symptoms associated with Parkinson's disease can be as varied as the motor symptoms."2.40Management of psychotic aspects of Parkinson's disease. ( Juncos, JL, 1999)
" Published studies have drawn criticism in terms of inappropriate titration schedules, nonequivalent dosing between treatment groups, short treatment duration, and inadequate sample sizes."2.40Clozapine: a comparison with other novel antipsychotics. ( Fleischhacker, WW, 1999)
" Considerable progress has been made in improving the motor side effect profile with the advent of clozapine and risperidone."2.39Side effect profiles of new antipsychotic agents. ( Casey, DE, 1996)
" However, no correlation between prolactin levels and dosage could be found."1.32[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics]. ( Fric, M; Laux, G, 2003)
"Patients reporting preexisting type 2 diabetes up to 8 months prior to observation were excluded."1.31Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. ( Gianfrancesco, FD; Grogg, AL; Mahmoud, RA; Nasrallah, HA; Wang, RH, 2002)
"Risperidone has a substantial cost advantage over olanzapine, and was preferred by psychiatrists for more indications."1.31Comparison of cost, dosage and clinical preference for risperidone and olanzapine. ( Kaplan, Z; Lichtenberg, P; Rabinowitz, J, 2000)
"Four patients affected by severe Parkinson's disease developed leucopenia (900-1200 WBC) during treatment of psychosis (3) or untreatable insomnia (1) with clozapine (37."1.31Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine. ( Bonanni, L; Gambi, F; Iacono, D; Onofrj, M; Thomas, A, 2000)
"Olanzapine is a relatively new antipsychotic agent which appears to be effective in the treatment of both the positive and negative symptoms of schizophrenia."1.30Olanzapine-induced mania. ( Brannon, GE; McBride, WA; Reeves, RR, 1998)
"Olanzapine is a new atypical antipsychotic agent that belongs to the same chemical class as clozapine."1.30In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study. ( Dresel, S; Hahn, K; Mager, T; Meisenzahl, E; Möller, HJ; Rossmüller, B; Tatsch, K, 1999)
"Twenty-one patients with Parkinson's disease and psychosis were included in an open-label 8-week trial of olanzapine."1.30Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. ( Aarsland, D; Larsen, JP; Lim, NG; Tandberg, E, 1999)
"Weight gain has been reported with nearly every antipsychotic drug on the market (molindone is an exception)."1.30Weight gain associated with antipsychotic drugs. ( Ganguli, R, 1999)
"Risperidone was more commonly used in combination with benzodiazepines and anticholinergics than olanzapine and clozapine, while clozapine was less likely to be combined with antidepressants and mood stabilisers."1.30Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. ( Altson, K; Bootle, A; Culhane, C; Doherty, P; Hope, J; Keks, NA; Krapivensky, N; Tanaghow, A, 1999)

Research

Studies (192)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's70 (36.46)18.2507
2000's121 (63.02)29.6817
2010's1 (0.52)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mao, M1
Skogh, E1
Scordo, MG1
Dahl, ML1
Linnet, K2
Olesen, OV2
Alfaro, CL1
Wudarsky, M1
Nicolson, R1
Gochman, P1
Sporn, A1
Lenane, M1
Rapoport, JL1
Voruganti, L1
Cortese, L1
Owyeumi, L1
Kotteda, V1
Cernovsky, Z1
Zirul, S1
Awad, A1
Friedman, JH1
Fernandez, HH1
Schmitt, GJ2
Meisenzahl, EM2
Dresel, S3
Tatsch, K3
Rossmüller, B3
Frodl, T2
Preuss, UW2
Hahn, K3
Möller, HJ3
Sattar, SP3
Gastfriend, DR1
Livingston, M1
Livingston, H1
Carrasco, JL1
Gutiérrez, M1
Gómez, JC1
Escobar, R1
Alvarez, E1
Cañas, F1
Bobes, J1
Gascón, J1
Gibert, J1
Wirshing, DA2
Boyd, JA1
Meng, LR1
Ballon, JS1
Marder, SR2
Wirshing, WC2
Gianfrancesco, FD1
Grogg, AL1
Mahmoud, RA1
Wang, RH1
Nasrallah, HA1
Lindenmayer, JP7
Czobor, P5
Volavka, J6
Lieberman, JA10
Citrome, L6
Sheitman, B5
Chakos, M5
McEvoy, JP3
Daniel, DG1
Meltzer, HY3
Alphs, L2
Green, AI2
Altamura, AC1
Anand, R2
Bertoldi, A1
Bourgeois, M1
Chouinard, G1
Islam, MZ1
Kane, J1
Krishnan, R1
Potkin, S1
Caro, JJ1
Ward, A1
Levinton, C1
Robinson, K1
Matthews, JD1
Bottonari, KA1
Polania, LM1
Mischoulon, D1
Dording, CM1
Irvin, R1
Fava, M1
Danileviciūte, V1
Duggan, L2
Fenton, M2
Dardennes, RM2
El-Dosoky, A2
Indran, S2
Cooper, TB4
Meibach, RC1
Hwang, JP1
Yang, CH1
Lee, TW1
Tsai, SJ1
Miller, TJ2
Zipursky, RB2
Perkins, D3
Addington, J2
Woods, SW4
Hawkins, KA2
Hoffman, R2
Preda, A1
Epstein, I1
Addington, D1
Lindborg, S2
Marquez, E1
Tohen, M6
Breier, A9
McGlashan, TH2
Taylor, DM1
Wright, T1
Libretto, SE1
Jerrell, JM1
Bloch, Y1
Vardi, O1
Mendlovic, S1
Levkovitz, Y1
Gothelf, D1
Ratzoni, G1
Gurovich, I1
Vempaty, A1
Lippmann, S1
Kopf, A1
Köster, J1
Schulz, A1
Krömker, H1
Becker, T1
Tollefson, G1
Gur, RE1
Kahn, R1
McEvoy, J3
Sharma, T1
Zipursky, R1
Wei, H1
Hamer, RM2
Potkin, SG1
Hsu, C1
Krishnan, KR1
Young, FK1
Meltzer, H1
Green, A1
Lambert, M1
Holzbach, R1
Moritz, S1
Postel, N1
Krausz, M1
Naber, D1
Bokszanska, A1
Martin, G1
Vanstraelen, M1
Holt, G2
Bouras, N2
Taylor, D1
Grant, K1
Bhatia, S1
Petty, F1
Schatz, RA1
Raja, M1
Azzoni, A1
Bhatia, SC1
Reeves, RR2
Torres, RA1
Harvey, PD1
Napolitano, JA1
Mao, L1
Gharabawi, G1
Fric, M1
Laux, G1
Sikich, L1
Bashford, RA1
Sheitman, BB1
Karagianis, JL3
LeDrew, KK1
Walker, DJ1
Feldman, PD5
Kaiser, CJ1
Kennedy, JS1
Sutton, VK1
Tran, PV7
Tollefson, GD10
Zhang, F2
Archie, S1
Wilson, JH1
Osborne, S1
Hobbs, H1
McNiven, J1
Ross, RG1
Novins, D1
Farley, GK1
Adler, LE1
Hoeh, N1
Gyulai, L1
Weintraub, D1
Streim, J1
Baksh, A1
Waage, IM1
Gedde-Dahl, A1
Fibiger, HC1
Wolters, EC1
Jansen, EN1
Tuynman-Qua, HG1
Bergmans, PL1
Casey, DE2
Lehman, AF1
Fulton, B1
Goa, KL1
Beasley, CM5
Street, JS4
Krueger, JA1
Tamura, RN3
Graffeo, KA1
Thieme, ME1
Reus, VI1
Glazer, WM1
Meyer, JM1
Simpson, GM1
Potvin, JH2
Hamilton, SH1
Kuntz, AJ2
Andersen, SW1
Beasley, C2
Weizer, M1
Levy, A1
Davidson, M1
Schooler, NR2
Zarate, CA1
Hillard, JR1
al Jeshi, A1
Gheuens, J1
Grebb, JA1
Gupta, S2
Droney, T1
Al-Samarrai, S1
Keller, P1
Frank, B1
Kasper, S1
Küfferle, B1
Landry, P1
Cournoyer, J1
Krishnamoorthy, J1
King, BH1
Phan, TG1
Yu, RY1
Hersch, MI1
Rudnick, A1
Spellberg, BJ1
Erhart, SM1
Bruneau, MA1
Stip, E1
Rosen, EH1
McBride, WA1
Brannon, GE1
Dellva, MA1
Wentley, AL1
Gazzola, LR1
Opler, LA1
Sanger, TM3
Grundy, S1
Jeste, DV3
Rockwell, E1
Harris, MJ1
Lohr, JB1
Lacro, J1
Fertig, MK1
Brooks, VG1
Shelton, PS1
English, CW1
Sanders, RD1
Mossman, D1
Soutullo, CA1
Keck, PE3
McElroy, SL1
Johnson, V1
Bruxner, G1
Kane, JM1
Reich, J1
Lu, Y1
Berg, PH2
Tandon, R1
Milner, K1
Jibson, MD1
Juncos, JL1
Buckley, PF1
Fanous, A1
Fleischhacker, WW1
Swartz, C1
Walder, M1
Mager, T2
Meisenzahl, E1
Aarsland, D1
Larsen, JP1
Lim, NG1
Tandberg, E1
Weiss, EL1
Longhurst, JG1
Bowers, MB1
Mazure, CM1
Stahl, SM1
Vercueil, L1
Foucher, J1
Madhusoodanan, S3
Suresh, P2
Brenner, R3
Pillai, R1
Meissner, W1
Schmidt, T1
Kupsch, A1
Trottenberg, T1
Lempert, T1
Benazzi, F2
Kostakoğlu, AE1
Rezaki, M1
Göğüş, A1
Ganguli, R1
Gheorghiu, S1
Knobler, HY1
Drumer, D1
Wolfgang, SA1
Simon, AE2
Aubry, JM2
Malky, L1
Bertschy, G2
Osser, DN1
Najarian, DM1
Dufresne, RL1
Olie, JP1
Ghaoui, S1
Bayle, FJ2
Keks, NA1
Altson, K1
Hope, J1
Krapivensky, N1
Culhane, C1
Tanaghow, A1
Doherty, P1
Bootle, A1
Solomons, K1
Geiger, O1
Compton, MT2
Saldivia, A1
Berry, SA1
Concepcion, NM1
Florita, CD1
Menon, G1
Kaur, A1
Nunez, G1
Reddy, H1
Conley, RR2
Chengappa, KN1
Pollock, BG2
Parepally, H1
Levine, J1
Kirshner, MA1
Brar, JS1
Zoretich, RA1
Williams, H1
Clarke, R1
Martin, J1
Karagianis, J1
Pillmann, F1
Schlote, K1
Broich, K1
Marneros, A1
Singh, HK1
Markowitz, GD1
Myers, G1
Haberfellner, EM1
Rigalleau, V1
Gatta, B1
Bonnaud, S1
Masson, M1
Bourgeois, ML1
Vergnot, V1
Gin, H1
Clark, WS4
Gannon, KS1
Cummings, JL2
Bymaster, FP1
Mitan, SJ2
Kadam, DL2
Rhoads, E1
Melkersson, KI1
Hulting, AL1
Brismar, KE1
Kinon, BJ2
Basson, BR2
Gilmore, JA2
Malcolm, S1
Stauffer, VL1
Teter, CJ1
Early, JJ1
Frachtling, RJ1
Rabinowitz, J1
Lichtenberg, P1
Kaplan, Z1
Weintraub, E1
Robinson, C1
Feifel, D1
Ghaemi, SN1
Stolar, M1
Sernyak, MJ1
Charney, DS1
Schmitt, A1
Braus, DF1
Littrell, KH1
Johnson, CG1
Hilligoss, NM1
Peabody, CD1
Littrell, SH1
Onofrj, M1
Thomas, A1
Bonanni, L1
Iacono, D1
Gambi, F1
Kapur, S1
Seeman, P1
Dawe, IC1
Thakur, A1
Bégin, S1
Raskin, J1
Roychowdhury, SM1
Czekalla, J1
Kollack-Walker, S1
Floris, M1
Lejeune, J1
Deberdt, W1
Risch, SC1
McGurk, S1
Horner, MD1
Nahas, Z1
Owens, SD1
Molloy, M1
Gilliard, C1
Christie, S1
Markowitz, JS1
DeVane, CL1
Mintzer, J1
George, MS1
Mahmoud, R1
Goodnick, PJ1
Barrios, CA1
Zorn, SH1
Miller, AH1
Narendran, R1
Young, CM1
Valenti, AM1
Pristach, CA1
Pato, MT1
Grace, JJ1
Khan, A1
Khan, SR1
Leventhal, RM1
Brown, WA1
Haapasalo-Pesu, KM1
Saarijärvi, S1
Dervaux, A1
Mascarenhas, N1
Lambolez, T1
Malek-Ahmadi, P1
Simpson, MM1
Goetz, RR1
Devlin, MJ1
Goetz, SA1
Walsh, BT1
Friedlander, R1
Lazar, S1
Klancnik, J1
Songer, DA1
Barclay, JC1
Schneider, LS1
Tariot, PN1
Lyketsos, CG1
Dagerman, KS1
Davis, KL1
Davis, S1
Hsiao, JK1
Katz, IR1
Olin, JT1
Rabins, PV1
Rosenheck, RA1
Small, GW1
Lebowitz, B1
Chroni, E1
Lekka, NP1
Tsibri, E1
Economou, A1
Paschalis, C1
Juliar, BE1
Baptista, T1
Beaulieu, S1
Rojas, P1
Arancibia, P1
Bravo, V1
Varela, S1
Van Meter, SA1
Seaburg, H1
McLendon, B1
Doraiswamy, PM1
Nelson, EB1
Rielage, E1
Welge, JA1
Ellingrod, VL1
Schultz, SK1
Ekstam-Smith, K1
Kutscher, E1
Turvey, C1
Arndt, S1
Parker, G1
Malhi, G1
Street, J1
Masterman, D1
Risser, RC1
de Haan, L1
Beuk, N1
Hoogenboom, B1
Dingemans, P1
Linszen, D1
Fawcett, RG1
Mathias, S1
Schaaf, LW1
Sonntag, A1
Ramankutty, G1
Sinha, S1
Bogunovic, O1
Riccitelli, G1
Baker, N1
Bilder, RM1
Goldman, RS1
Hoptman, M1
Kunz, M1
Horowitz, TL1
Llorca, PM1
Chereau, I1
Lancon, C1
Del Paggio, D1
Finley, PR1
Cavano, JM1
Patel, NC1
Dorson, PG1
Edwards, N1
Mendelson, S1
Crismon, ML1
Virkkunen, M1
Wahlbeck, K1
Rissanen, A1
Naukkarinen, H1
Franssila-Kallunki, A1
Mendhekar, DN1
War, L1
Sharma, JB1
Jiloha, RC1

Clinical Trials (11)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome[NCT00529308]Phase 220 participants (Actual)Interventional2007-07-31Completed
Aripiprazole for Clozapine Associated Medical Morbidity[NCT00345033]Phase 438 participants (Actual)Interventional2005-03-31Completed
An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000]Phase 424 participants (Actual)Interventional2005-01-31Completed
Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department[NCT04260607]Phase 32 participants (Actual)Interventional2020-01-14Terminated (stopped due to As a busy MTF we were unable to retain a health care provider with the appropriate expertise to buy-in to this study once the initiating PI left military service.)
Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness[NCT00661869]295 participants (Actual)Interventional2006-09-30Completed
A Double-Blind, Placebo-Controlled Trial of Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment: Bergman's Minimal Model Analysis[NCT00337350]Phase 420 participants (Actual)Interventional2003-09-30Completed
A Clinical Trial Of Weight Reduction in Schizophrenia[NCT00158366]261 participants (Actual)Interventional2004-05-31Completed
A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia[NCT00351936]Phase 416 participants (Actual)Interventional2005-12-31Completed
Switching Antipsychotics: Abrupt Discontinuation Versus Overlap[NCT02640300]Phase 433 participants (Actual)Interventional1999-05-31Completed
[NCT01615185]Phase 496 participants (Actual)Interventional2008-01-31Terminated
Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)[NCT00015548]450 participants Interventional2001-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

"Number of Patients With Improved or Minimally Improved in Clinical Global Impression-Improvement (CGI) Scale"

"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks

Interventionparticipants (Number)
Active2
Sham8

"Number of Patients With Much Improved or Very Much Improved on Clinical Global Impression-Improvement (CGI) Scale"

"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks

Interventionparticipants (Number)
Active1
Sham0

Motor Cortex Excitability Normalization-Left Motor Threshold

Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks

InterventionµV (Mean)
Active56.5
Sham63.8

Motor Cortex Excitability Normalization-Right Motor Threshold

Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks

InterventionµV (Mean)
Active56
Sham59.8

Yale Global Tic Severity Scale (Y-GTSS)

Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall impairment associated with tics. (NCT00529308)
Timeframe: 3 weeks

Interventionunits on a scale (Mean)
Active29.5
Sham31.5

Change in Body Mass Index (BMI)

A comparison between aripiprazole group and placebo group of change in Body Mass Index (BMI) measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8

Interventionkg/m^2 (Mean)
Aripiprazole-0.52
Placebo0.03

Change in Glucose Metabolism

A comparison between the aripiprazole group and placebo group in change in glucose metabolism measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8

Interventionmin^-1 (Mean)
Aripiprazole0.003
Placebo-0.005

Change in Insulin Resistance

A comparison between aripiprazole group and placebo group of change in insulin resistance measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8

InterventionHOMA score (Mean)
Aripiprazole0.6
Placebo0.65

Change in Total Cholesterol

A comparison of aripiprazole group and placebo group in change in total cholesterol measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8

Interventionmg/dL (Mean)
Aripiprazole-15.3
Placebo5.6

Change in Triglycerides

(NCT00345033)
Timeframe: Measured at Baseline and Week 8

Interventionmg/dL (Mean)
Aripiprazole-5.9
Placebo-7.3

Change in Weight

A comparison between aripiprazole group and placebo group in change in weight measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8

Interventionkg (Mean)
Aripiprazole-1.5
Placebo0.3

Change From Baseline in Fasting Glucose

Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6

Interventionmg/dL (Mean)
Clozapine Treatment With Adjunctive Ziprasidone5
Olanzapine Treatment With Adjunctive Ziprasidone-4.5

Change From Baseline on Fasting Insulin

Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6

InterventionmicroIU/L (Mean)
Clozapine Treatment With Adjunctive Ziprasidone1
Olanzapine Treatment With Adjunctive Ziprasidone-0.9

Change From Baseline in Acute Insulin Response to Glucose (AIRG)

Acute insulin response to glucose (AIRG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. AIRG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. AIRG measures the acute(0-10 min) beta cell response to a glucose load calculated by the areas under the curve higher than basal insulin values. The AIRG was assessed as the incremental area under the curve (calculated by the trapezoid rule) from 0 to 10 min of the FSIVGTT. (NCT00337350)
Timeframe: baseline, week 8

InterventionUnits/mL per 10 minutes (Mean)
Rosiglitazone-151
Placebo19

Change From Baseline in Insulin Sensitivity

Insulin Sensitivity (IS) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in IS between Baseline and week 8. SI was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SI represents the increase in net fractional glucose clearance rate per unit change in serum insulin concentration after the intravenous glucose load (microUnits/mL). (NCT00337350)
Timeframe: baseline, week 8

InterventionmicroUnits/mL (Mean)
Rosiglitazone3.2
Placebo0.4

Change From Baseline on Glucose Utilization (SG)

Glucose utilization (SG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. SG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SG represents the net fractional glucose clearance rate because of the increase in glucose independent of any increase in circulating insulin concentrations above baseline. (NCT00337350)
Timeframe: baseline, week 8

Interventionmin^-1 (Mean)
Rosiglitazone.002
Placebo-0.01

Change From Baseline in Body Mass Index (BMI)

Evaluating change in Body Mass Index (BMI) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Interventionkg/m^2 (Mean)
Aripiprazole-0.4
Placebo0.3

Change From Baseline in Fasting Total Cholesterol

Evaluating change in fasting total cholesterol between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Interventionmg/dL (Mean)
Aripiprazole-3
Placebo9

Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)

Evaluating change in high-density lipoprotein cholesterol (HDL-C) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Interventionmg/dL (Mean)
Aripiprazole0.4
Placebo0.6

Change From Baseline in Low-density Lipoprotein (LDL)

Evaluating change in low-density lipoprotein (LDL) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Interventionmg/dL (Mean)
Aripiprazole-0.2
Placebo3.1

Change From Baseline in Triglycerides

Evaluating change in triglyceride levels between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Interventionmg/dL (Mean)
Aripiprazole-51.7
Placebo47.6

Change From Baseline in Waist-hip Ratio (WHR)

Evaluating change in waist-hip ratio (WHR) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Interventioncm (Mean)
Aripiprazole0.0
Placebo0.0

Change From Baseline in Weight (Lbs)

Evaluating change in weight (lbs) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Interventionlbs (Mean)
Aripiprazole-2.9
Placebo2.1

Reviews

40 reviews available for pirenzepine and Psychotic Disorders

ArticleYear
Atypical antipsychotics in Parkinson-sensitive populations.
    Journal of geriatric psychiatry and neurology, 2002,Fall, Volume: 15, Issue:3

    Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Dementia, Vascular; Dibenzothia

2002
Using antipsychotics in elderly patients.
    The Practitioner, 2002, Volume: 246, Issue:1639

    Topics: Aged; Antipsychotic Agents; Benzodiazepines; Delusions; Hallucinations; Humans; Olanzapine; Pirenzep

2002
Recent developments in pharmacotherapy for the acutely psychotic patient.
    Journal of emergency nursing, 2002, Volume: 28, Issue:6 Suppl

    Topics: Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Injections, Intr

2002
[Schizoaffective disorder: clinical symptoms and present-day approach to treatment].
    Medicina (Kaunas, Lithuania), 2002, Volume: 38, Issue:11

    Topics: Adolescent; Amisulpride; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Antimanic

2002
Olanzapine for schizophrenia.
    The Cochrane database of systematic reviews, 2003, Issue:1

    Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; Randomi

2003
[Life threatening neuroleptic malignant syndrome due to olanzapine].
    Psychiatrische Praxis, 2003, Volume: 30, Issue:5

    Topics: Antipsychotic Agents; Benzodiazepines; Critical Care; Electroconvulsive Therapy; Female; Haloperidol

2003
Olanzapine for psychotic and behavioral disturbances in Alzheimer disease.
    The Annals of pharmacotherapy, 2003, Volume: 37, Issue:9

    Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Humans; Mental Disorders; Olanzapine; Pire

2003
Pharmacologic management of psychosis in the elderly: a critical review.
    Journal of geriatric psychiatry and neurology, 2003, Volume: 16, Issue:4

    Topics: Aged; Alzheimer Disease; Benzodiazepines; Bipolar Disorder; Clozapine; Depressive Disorder; Drug Adm

2003
Olanzapine: a new typical antipsychotic drug.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 1996, Volume: 14, Issue:2

    Topics: Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Humans; Olanzapine; Pirenzepine; Ps

1996
Side effect profiles of new antipsychotic agents.
    The Journal of clinical psychiatry, 1996, Volume: 57 Suppl 11

    Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced;

1996
Evaluating outcomes of treatments for persons with psychotic disorders.
    The Journal of clinical psychiatry, 1996, Volume: 57 Suppl 11

    Topics: Antipsychotic Agents; Benzodiazepines; Drug Costs; Health Care Reform; Humans; Olanzapine; Pirenzepi

1996
Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses.
    Drugs, 1997, Volume: 53, Issue:2

    Topics: Animals; Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psychotic Disorders

1997
Olanzapine and the new generation of antipsychotic agents: patterns of use.
    The Journal of clinical psychiatry, 1997, Volume: 58 Suppl 10

    Topics: Antipsychotic Agents; Benzodiazepines; Child; Comorbidity; Dementia; Depressive Disorder; Developmen

1997
[New antipsychotic drugs].
    Harefuah, 1997, Volume: 133, Issue:1-2

    Topics: Antipsychotic Agents; Benzodiazepines; Benzothiazoles; Clinical Trials as Topic; Dibenzothiazepines;

1997
New antipsychotic medications: strategies for evaluation and selected findings.
    Schizophrenia research, 1997, Oct-30, Volume: 27, Issue:2-3

    Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clinical Trials as Topic; Clozapine; Drug Ad

1997
Antipsychotic agents and bipolar disorder.
    The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 1

    Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Cl

1998
Emergency treatment of acute psychosis.
    The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 1

    Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Decision Trees; Drug Administration

1998
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
    The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 12

    Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Tri

1998
Conventional vs. newer antipsychotics in elderly patients.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 1999,Winter, Volume: 7, Issue:1

    Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Dementia; Dibenzothiazepines; Dose-Re

1999
Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns.
    Schizophrenia research, 1999, Mar-01, Volume: 35 Suppl

    Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Disease Progressio

1999
Tardive dyskinesia in affective disorders.
    The Journal of clinical psychiatry, 1999, Volume: 60 Suppl 5

    Topics: Adult; Affective Disorders, Psychotic; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipol

1999
Review of recent clinical studies with olanzapine.
    The British journal of psychiatry. Supplement, 1999, Issue:37

    Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Depressive Disorder; Drug Resistance; Humans; Olan

1999
Antipsychotics from theory to practice: integrating clinical and basic data.
    The Journal of clinical psychiatry, 1999, Volume: 60 Suppl 8

    Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Trials as Topic; Cl

1999
Management of psychotic aspects of Parkinson's disease.
    The Journal of clinical psychiatry, 1999, Volume: 60 Suppl 8

    Topics: Algorithms; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; C

1999
The role of typical and atypical antipsychotic medications in the management of agitation and aggression.
    The Journal of clinical psychiatry, 1999, Volume: 60 Suppl 10

    Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Loxapine; Mental Disorders; Ol

1999
Clozapine: a comparison with other novel antipsychotics.
    The Journal of clinical psychiatry, 1999, Volume: 60 Suppl 12

    Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; Double-Blind

1999
[New antipsychotic agents].
    L'Encephale, 1999, Volume: 25 Spec No 3

    Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Imidazole

1999
Olanzapine for schizophrenia.
    The Cochrane database of systematic reviews, 2000, Issue:2

    Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; Schizop

2000
Adverse events related to olanzapine.
    The Journal of clinical psychiatry, 2000, Volume: 61 Suppl 8

    Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Mass In

2000
Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:9

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dose-Response Relationship, Drug; Fe

2000
Rationale and guidelines for the inpatient treatment of acute psychosis.
    The Journal of clinical psychiatry, 2000, Volume: 61 Suppl 14

    Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Administration Schedule; Drug

2000
New treatments for bipolar disorder: the role of atypical neuroleptic agents.
    The Journal of clinical psychiatry, 2000, Volume: 61 Suppl 14

    Topics: Acute Disease; Algorithms; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazep

2000
Consistency of atypical antipsychotic superiority to placebo in recent clinical trials.
    Biological psychiatry, 2001, Jan-01, Volume: 49, Issue:1

    Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dibenzothiazepines; Humans; Olanzap

2001
Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
    The American journal of psychiatry, 2001, Volume: 158, Issue:3

    Topics: Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Dopamine D2 Receptor Antagonists; Haloperid

2001
Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.
    The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 2

    Topics: Acute Disease; Antipsychotic Agents; Arrhythmias, Cardiac; Benzodiazepines; Death, Sudden; Female; H

2001
Use of olanzapine in non-psychotic psychiatric disorders.
    Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:4

    Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorder; Humans; Ol

2001
The pharmacology of weight gain with antipsychotics.
    The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 7

    Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Eating; Humans; Olanz

2001
Priapism associated with conventional and atypical antipsychotic medications: a review.
    The Journal of clinical psychiatry, 2001, Volume: 62, Issue:5

    Topics: Antipsychotic Agents; Benzodiazepines; Circadian Rhythm; Clozapine; Erectile Dysfunction; Female; Fo

2001
Use of olanzapine for elderly patients with psychotic disorders: a review.
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2001, Volume: 13, Issue:4

    Topics: Aged; Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; R

2001
Tardive dyskinesias and antipsychotics: a review.
    European psychiatry : the journal of the Association of European Psychiatrists, 2002, Volume: 17, Issue:3

    Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; Humans; Ola

2002

Trials

55 trials available for pirenzepine and Psychotic Disorders

ArticleYear
Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study.
    Schizophrenia research, 2002, Oct-01, Volume: 57, Issue:2-3

    Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Huma

2002
Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine.
    Journal of psychopharmacology (Oxford, England), 2002, Volume: 16, Issue:3

    Topics: Adult; Aged; Antipsychotic Agents; Benzamides; Benzodiazepines; Contrast Media; Corpus Striatum; Dop

2002
Treatment of severely psychotic inpatients with schizophrenia: olanzapine versus other antipsychotic drugs.
    International clinical psychopharmacology, 2002, Volume: 17, Issue:6

    Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male;

2002
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:10

    Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cross-Over Studies; Double-Bli

2002
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).
    Archives of general psychiatry, 2003, Volume: 60, Issue:1

    Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; Male; Middle Ag

2003
An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Depressive Disord

2002
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    The American journal of psychiatry, 2003, Volume: 160, Issue:2

    Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Clozapine; Double-Bl

2003
The efficacy and safety of olanzapine for the treatment of geriatric psychosis.
    Journal of clinical psychopharmacology, 2003, Volume: 23, Issue:2

    Topics: Acute Disease; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male;

2003
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.
    Schizophrenia research, 2003, May-01, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Comorbidity; Depressive

2003
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design.
    Schizophrenia research, 2003, May-01, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Child; Diagnostic and Statistical Manual o

2003
Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications.
    Schizophrenia bulletin, 2002, Volume: 28, Issue:4

    Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Diagnostic and Stat

2002
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
    The American journal of psychiatry, 2003, Volume: 160, Issue:8

    Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Metho

2003
Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial.
    Biological psychiatry, 2003, Aug-15, Volume: 54, Issue:4

    Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; Male; Middle Aged; Ol

2003
Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders.
    International clinical psychopharmacology, 2003, Volume: 18, Issue:5

    Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Fe

2003
Risperidone and olanzapine in adults with intellectual disability: a clinical naturalistic study.
    International clinical psychopharmacology, 2003, Volume: 18, Issue:5

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Comorbidity; Di

2003
Potential use of olanzapine in treatment of substance dependence disorders.
    Journal of clinical psychopharmacology, 2003, Volume: 23, Issue:4

    Topics: Alcoholism; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cocaine-Related Disorders; Huma

2003
Comparison of three antipsychotics in the emergency psychiatric setting.
    Human psychopharmacology, 2003, Volume: 18, Issue:6

    Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Emergency Services,

2003
Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder.
    International journal of geriatric psychiatry, 2003, Volume: 18, Issue:9

    Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Double-Blind Method; Female; Human

2003
A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2004, Volume: 29, Issue:1

    Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Dose-Response Relationship, Drug; Double-B

2004
Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up.
    Current medical research and opinion, 2003, Volume: 19, Issue:6

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Follow-Up Studies; Hospitalization; Humans; Ma

2003
A 1-year open-label trial of olanzapine in school-age children with schizophrenia.
    Journal of child and adolescent psychopharmacology, 2003,Fall, Volume: 13, Issue:3

    Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Drug Resistance; Female; Humans; Male; Ola

2003
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    The American journal of psychiatry, 1997, Volume: 154, Issue:4

    Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depre

1997
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
    The American journal of psychiatry, 1997, Volume: 154, Issue:9

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administration

1997
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.
    Journal of clinical psychopharmacology, 1997, Volume: 17, Issue:5

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Dyskinesia, Drug-Induced; Female;

1997
Comments on "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" by Tran and Associates.
    Journal of clinical psychopharmacology, 1998, Volume: 18, Issue:4

    Topics: Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Humans; Olanzapine; Pirenzepine; Psychot

1998
Open-label olanzapine treatment in five preadolescent children.
    Journal of child and adolescent psychopharmacology, 1998, Volume: 8, Issue:2

    Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzod

1998
Olanzapine versus haloperidol treatment in first-episode psychosis.
    The American journal of psychiatry, 1999, Volume: 156, Issue:1

    Topics: Age of Onset; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric Ratin

1999
An open trial of olanzapine in patients with treatment-refractory psychoses.
    Journal of clinical psychopharmacology, 1999, Volume: 19, Issue:1

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Monitoring; Female; Humans; Male; Middle Aged; Ol

1999
Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy.
    The British journal of psychiatry : the journal of mental science, 1999, Volume: 174

    Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperido

1999
Schizophrenia and schizoaffective disorder treated with high doses of olanzapine.
    Journal of clinical psychopharmacology, 1999, Volume: 19, Issue:3

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-Blind Method;

1999
The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome.
    Biological psychiatry, 1999, Aug-01, Volume: 46, Issue:3

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-Blind Method;

1999
Olanzapine in whole, not half, tablets for psychosis from Alzheimer's dementia.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1999, Nov-01, Volume: 56, Issue:21

    Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Humans; Olanzapine; P

1999
Olanzapine increases weight and serum triglyceride levels.
    The Journal of clinical psychiatry, 1999, Volume: 60, Issue:11

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Female; Hospitalizat

1999
Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study.
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2000, Volume: 12, Issue:1

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Drug Interactions; Dyskinesia, Drug-

2000
Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine.
    Journal of clinical psychopharmacology, 2000, Volume: 20, Issue:3

    Topics: Adult; Antipsychotic Agents; Atropine; Autonomic Nervous System Diseases; Benzodiazepines; Cholinerg

2000
Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.
    Archives of general psychiatry, 2000, Volume: 57, Issue:10

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Behavioral Symptoms; Benzodiazepin

2000
Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:11

    Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Administrat

2000
D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.
    Journal of psychopharmacology (Oxford, England), 2000, Volume: 14, Issue:4

    Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Benzodiazepines; Brain; Brain Chemi

2000
Switching clozapine responders to olanzapine.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:12

    Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Adm

2000
The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.
    The Journal of clinical psychiatry, 2001, Volume: 62, Issue:1

    Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Delus

2001
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
    The Journal of clinical psychiatry, 2001, Volume: 62, Issue:2

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Blood Pressure; Body Mass Index; Body W

2001
Effect of amantadine on weight gain during olanzapine treatment.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2001, Volume: 11, Issue:2

    Topics: Adult; Amantadine; Antipsychotic Agents; Benzodiazepines; Dopamine Agents; Female; Humans; Male; Ola

2001
A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates.
    Neurocase, 2001, Volume: 7, Issue:2

    Topics: Adult; Basal Ganglia; Benzodiazepines; Brain; Brain Mapping; Cognition Disorders; Cross-Over Studies

2001
A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
    The American journal of psychiatry, 2001, Volume: 158, Issue:5

    Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Method; Drug Admi

2001
Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study.
    The Journal of clinical psychiatry, 2001, Volume: 62, Issue:7

    Topics: Adult; Affective Disorders, Psychotic; Aged; Anticonvulsants; Antipsychotic Agents; Benzodiazepines;

2001
Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
    Psychiatric services (Washington, D.C.), 2001, Volume: 52, Issue:11

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Double-Bl

2001
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2001,Fall, Volume: 9, Issue:4

    Topics: Aged; Algorithms; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Citalopram; Cost-Benefit

2001
Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia.
    International journal of geriatric psychiatry, 2001, Volume: 16 Suppl 1

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Benzodiazepines; Dose-Response Rela

2001
An open trial of olanzapine in the treatment of patients with psychotic depression.
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2001, Volume: 13, Issue:3

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Female; Humans; Male; Olan

2001
Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis.
    Pharmacotherapy, 2002, Volume: 22, Issue:1

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cognition; Dementia; Female; Humans;

2002
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
    The American journal of psychiatry, 2002, Volume: 159, Issue:2

    Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Double-Blind M

2002
Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies.
    Dementia and geriatric cognitive disorders, 2002, Volume: 13, Issue:2

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Behavior; Benzodiazepines; Cognition; Delusions; Dose

2002
Olanzapine versus haloperidol in schizoaffective disorder, bipolar type.
    Journal of affective disorders, 2001, Volume: 67, Issue:1-3

    Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind M

2001
Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:2

    Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Comorbidity; Female; Humans; Longitudin

2002
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
    The American journal of psychiatry, 2002, Volume: 159, Issue:6

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Double-Blind Method; Female; Hal

2002

Other Studies

97 other studies available for pirenzepine and Psychotic Disorders

ArticleYear
Interindividual variation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serum and upstream FMO polymorphisms in cerebrospinal fluid.
    Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:2

    Topics: Antipsychotic Agents; Benzodiazepines; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Female; Hum

2012
Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication.
    Therapeutic drug monitoring, 2002, Volume: 24, Issue:4

    Topics: Adult; Aged; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Carbamazepine; Chromatography,

2002
Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine.
    Journal of child and adolescent psychopharmacology, 2002,Summer, Volume: 12, Issue:2

    Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Child; Clozapine; Double-Blind Method; Fem

2002
Olanzapine-induced hyperventilation: case report.
    Journal of psychiatry & neuroscience : JPN, 2002, Volume: 27, Issue:5

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Humans; Hyperventilation; Male; Olanzapine; Pirenzepin

2002
The effects of novel antipsychotics on glucose and lipid levels.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:10

    Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL

2002
The effects of novel antipsychotics on glucose and lipid levels.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:10

    Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL

2002
The effects of novel antipsychotics on glucose and lipid levels.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:10

    Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL

2002
The effects of novel antipsychotics on glucose and lipid levels.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:10

    Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL

2002
Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:10

    Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Comorbidity; Confidence Inte

2002
The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:12

    Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Diabetes Mellitus; Female; Follow-Up St

2002
Comparative effectiveness of antipsychotic drugs.
    The American journal of psychiatry, 2003, Volume: 160, Issue:3

    Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Trials as Topic; Clozapine;

2003
Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
    The Journal of clinical psychiatry, 2003, Volume: 64, Issue:5

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Cost-Benefit Analysis; Costs and Cost

2003
Hyperglycemia from olanzapine treatment in adolescents.
    Journal of child and adolescent psychopharmacology, 2003,Spring, Volume: 13, Issue:1

    Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Diabetes Mellitus, Type 2; Female;

2003
QTc prolongation: chlorpromazine and high-dosage olanzapine.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2003, Volume: 48, Issue:5

    Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Female; Health Status

2003
Olanzapine for cocaine cravings and relapse prevention.
    The Journal of clinical psychiatry, 2003, Volume: 64, Issue:8

    Topics: Antipsychotic Agents; Behavior, Addictive; Benzodiazepines; Cocaine-Related Disorders; Comorbidity;

2003
Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia.
    Southern medical journal, 2003, Volume: 96, Issue:7

    Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Benzodiazepi

2003
[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].
    Psychiatrische Praxis, 2003, Volume: 30 Suppl 2

    Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzothiaze

2003
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.
    The Journal of clinical psychiatry, 2003, Volume: 64, Issue:9

    Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Depression; Double

2003
Pilot study: access to fitness facility and exercise levels in olanzapine-treated patients.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2003, Volume: 48, Issue:9

    Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Exercise; Female; Fitness Centers; Health

2003
High-dose olanzapine and prolactin levels.
    The Journal of clinical psychiatry, 2003, Volume: 64, Issue:10

    Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug

2003
Pulmonary embolism possibly associated with olanzapine treatment.
    BMJ (Clinical research ed.), 2003, Dec-13, Volume: 327, Issue:7428

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Humans; Male; Olanzapine; Pirenzepine; Psychotic Disor

2003
Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease.
    Neurology, 1996, Volume: 47, Issue:4

    Topics: Aged; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middle Aged; Olanzapine; Parkinso

1996
Antipsychotic drug choices now include olanzapine.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1996, Dec-01, Volume: 53, Issue:23

    Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psychotic Disorders

1996
Olanzapine: a novel atypical neuroleptic agent.
    Lancet (London, England), 1997, May-03, Volume: 349, Issue:9061

    Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Humans; Olanzapine; Pirenzepine; Ps

1997
From chlorpromazine to olanzapine: a brief history of antipsychotics.
    Psychiatric services (Washington, D.C.), 1997, Volume: 48, Issue:9

    Topics: Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; History, 20th Century; Humans; Ola

1997
Paranoia and agitation associated with olanzapine treatment.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1998, Volume: 43, Issue:2

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanzapine; Paranoid Disorders;

1998
Comments on article by Tran and colleagues, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders".
    Journal of clinical psychopharmacology, 1998, Volume: 18, Issue:2

    Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; Risperi

1998
Comments on article by Tran and associates, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders".
    Journal of clinical psychopharmacology, 1998, Volume: 18, Issue:2

    Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; Risperi

1998
Olanzapine-induced weight gain.
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 1998, Volume: 10, Issue:1

    Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middle Aged; Olanzapine; P

1998
Acute dystonia with olanzapine.
    The Journal of clinical psychiatry, 1998, Volume: 59, Issue:7

    Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Dystonia; Female; Humans; Male; Middle Aged; O

1998
Hypothermia induced by risperidone and olanzapine in a patient with Prader-Willi syndrome.
    The Medical journal of Australia, 1998, Aug-17, Volume: 169, Issue:4

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Humans; Hypothermia

1998
Quality of life and atypical antipsychotics.
    Journal of clinical psychopharmacology, 1998, Volume: 18, Issue:5

    Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psych

1998
Novel antipsychotics and new onset diabetes.
    Biological psychiatry, 1998, Oct-15, Volume: 44, Issue:8

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Humans; Male; Mi

1998
Metronome or alternating Pisa syndrome: a form of tardive dystonia under clozapine treatment.
    International clinical psychopharmacology, 1998, Volume: 13, Issue:5

    Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; Female; Humans; Middle A

1998
Olanzapine and negative symptoms.
    The Journal of clinical psychiatry, 1998, Volume: 59, Issue:10

    Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Male; Middle Aged; Olanzapine; Pire

1998
Olanzapine-induced mania.
    The Journal of the American Osteopathic Association, 1998, Volume: 98, Issue:10

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Male; Olanzapine; Pirenzepin

1998
Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses.
    The British journal of psychiatry : the journal of mental science, 1998, Volume: 172

    Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Hal

1998
Return of menstruation after switching from risperidone to olanzapine.
    Journal of clinical psychopharmacology, 1998, Volume: 18, Issue:6

    Topics: Adult; Amenorrhea; Antipsychotic Agents; Benzodiazepines; Female; Humans; Menstruation; Olanzapine;

1998
Hyperglycemia associated with olanzapine.
    The Journal of clinical psychiatry, 1998, Volume: 59, Issue:12

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2;

1998
Olanzapine in the treatment of tardive dyskinesia: a report of two cases.
    Journal of clinical psychopharmacology, 1999, Volume: 19, Issue:1

    Topics: Adult; Alcoholism; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Humans; Male; Mi

1999
Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication.
    Therapeutic drug monitoring, 1999, Volume: 21, Issue:1

    Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cytochrome P-450 CYP2D6 Inhibitors; Drug I

1999
Neuroleptic malignant syndrome associated with olanzapine.
    The Australian and New Zealand journal of psychiatry, 1998, Volume: 32, Issue:6

    Topics: Aged; Antipsychotic Agents; Benzodiazepines; Diagnosis, Differential; Humans; Male; Neuroleptic Mali

1998
New antipsychotic drugs produce better outcomes.
    Healthcare benchmarks, 1997, Volume: 4, Issue:10

    Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Disease Management; Drug Costs; Humans; Mental Hea

1997
Use of high-dose olanzapine in refractory psychosis.
    The American journal of psychiatry, 1999, Volume: 156, Issue:4

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Humans; Male; Olanzapine

1999
Hypofrontal symptoms from olanzapine: a case report.
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 1999, Volume: 11, Issue:1

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Humans; Male; Olanzapine; Pirenzepine; Psychotic Disor

1999
In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.
    European journal of nuclear medicine, 1999, Volume: 26, Issue:8

    Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Benzodiazepines; Case-Control Studi

1999
Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.
    The Journal of neuropsychiatry and clinical neurosciences, 1999,Summer, Volume: 11, Issue:3

    Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dementia; Dose-Response Relationship, Drug; Female; Hum

1999
Olanzapine for treatment-refractory psychosis in patients responsive to, but intolerant of, clozapine.
    Journal of clinical psychopharmacology, 1999, Volume: 19, Issue:4

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Female; H

1999
Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?
    The Journal of clinical psychiatry, 1999, Volume: 60, Issue:7

    Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Therapy, Combination; Hum

1999
Risperidone-induced tardive dystonia and psychosis.
    Lancet (London, England), 1999, Mar-20, Volume: 353, Issue:9157

    Topics: Antipsychotic Agents; Benzodiazepines; Dystonia; Facial Muscles; Humans; Male; Middle Aged; Neck Mus

1999
Experience with the atypical antipsychotics--risperidone and olanzapine in the elderly.
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 1999, Volume: 11, Issue:3

    Topics: Aged; Aged, 80 and over; Aging; Antipsychotic Agents; Benzodiazepines; Comorbidity; Female; Geriatri

1999
Reversible leucopenia related to olanzapine.
    Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14, Issue:5

    Topics: Benzodiazepines; Female; Humans; Leukopenia; Male; Middle Aged; Olanzapine; Pirenzepine; Psychotic D

1999
Olanzapine-induced psychotic mania in bipolar schizoaffective disorder.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1999, Volume: 44, Issue:6

    Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Female; Humans; Middle Aged; Olanzapine; Pi

1999
Early relapse of psychotic symptoms after an initial response to olanzapine.
    Acta psychiatrica Scandinavica, 1999, Volume: 100, Issue:4

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Binding, Competitive; Brief Psychiatric Rating Scale;

1999
Weight gain associated with antipsychotic drugs.
    The Journal of clinical psychiatry, 1999, Volume: 60 Suppl 21

    Topics: Administration, Oral; Antipsychotic Agents; Benzodiazepines; Clozapine; Delayed-Action Preparations;

1999
Recurrence of neuroleptic malignant syndrome with olanzapine treatment.
    The American journal of psychiatry, 1999, Volume: 156, Issue:11

    Topics: Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Chlorprothixene; Clopenthixol; Female

1999
Hypomania-like syndrome induced by olanzapine.
    International clinical psychopharmacology, 1999, Volume: 14, Issue:6

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Female; Humans; Olanzapine; Pirenzep

1999
Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service.
    The Australian and New Zealand journal of psychiatry, 1999, Volume: 33, Issue:6

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Community Mental Health Services; Dose-Resp

1999
[Away from life into a trance. Story of an admission].
    Psychiatrische Praxis, 2000, Volume: 27, Issue:1

    Topics: Antipsychotic Agents; Autobiographies as Topic; Benzodiazepines; Commitment of Mentally Ill; Humans;

2000
Olanzapine-induced psychotic mania in bipolar schizo-affective disorder.
    European psychiatry : the journal of the Association of European Psychiatrists, 1999, Volume: 14, Issue:7

    Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Female; Humans; Middle Aged; Olanzapine; Pi

1999
Tardive dyskinesia in older patients.
    The Journal of clinical psychiatry, 2000, Volume: 61 Suppl 4

    Topics: Adult; Age Factors; Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiaz

2000
Olanzapine use in the elderly: a retrospective analysis.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2000, Volume: 45, Issue:2

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middle Aged; O

2000
Recurrent priapism during treatment with clozapine and olanzapine.
    The American journal of psychiatry, 2000, Volume: 157, Issue:4

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Interactions; Humans; Male; Olanzapine

2000
Olanzapine and tardive dyskinesia.
    The British journal of psychiatry : the journal of mental science, 1999, Volume: 175

    Topics: Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Haloperidol; Humans; Olanzapine; Pi

1999
Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability.
    Journal of intellectual disability research : JIDR, 2000, Volume: 44 ( Pt 2)

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Female; Follow-Up St

2000
Olanzapine and weight gain.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2000, Volume: 45, Issue:5

    Topics: Adult; Benzodiazepines; Female; Humans; Obesity; Olanzapine; Pirenzepine; Psychotic Disorders; Selec

2000
Electroencephalogram alterations during treatment with olanzapine.
    Psychopharmacology, 2000, Volume: 150, Issue:2

    Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Electroencephalography; Female; Humans; Ma

2000
Esotropia associated with olanzapine.
    Journal of clinical psychopharmacology, 2000, Volume: 20, Issue:4

    Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Depressive Disorder; Esotropia; Female; Humans; O

2000
Remission of tardive dyskinesia after changing from flupenthixol to olanzapine.
    European psychiatry : the journal of the Association of European Psychiatrists, 2000, Volume: 15, Issue:5

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dopamine Antagonists; Dyskinesia, Drug-Induced; Flupen

2000
Diabetes as a result of atypical anti-psychotic drugs--a report of three cases.
    Diabetic medicine : a journal of the British Diabetic Association, 2000, Volume: 17, Issue:6

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Depressive Disorder; Diabetes Mellitus; Gly

2000
Polypharmacy of 2 atypical antipsychotics.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:9

    Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Drug Administrat

2000
Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:10

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Chromatography, High Press

2000
Olanzapine-induced neutropenia in patients with history of clozapine treatment: two case reports from a state psychiatric institution.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:11

    Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Drug Administrat

2000
Comparison of cost, dosage and clinical preference for risperidone and olanzapine.
    Schizophrenia research, 2000, Dec-15, Volume: 46, Issue:2-3

    Topics: Antipsychotic Agents; Benzodiazepines; Drug Utilization; Humans; Israel; Olanzapine; Pirenzepine; Pr

2000
A case of monosymptomatic hypochondriacal psychosis treated with olanzapine.
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2000, Volume: 12, Issue:4

    Topics: Aged; Antipsychotic Agents; Benzodiazepines; Female; Humans; Hypochondriasis; Olanzapine; Pirenzepin

2000
[Effective treatment of depressive disorder with psychotic symptoms by olanzapine combination therapy].
    Deutsche medizinische Wochenschrift (1946), 2000, Dec-15, Volume: 125, Issue:50

    Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Depressive Disorder

2000
Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2000, Volume: 21, Issue:4

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationshi

2000
Rapid tranquilization with olanzapine in acute psychosis: a case series.
    The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 2

    Topics: Acute Disease; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Drug Administration Sc

2001
Introduction: a new era in the pharmacotherapy of psychotic disorders.
    The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 2

    Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Administration Schedule

2001
Hypothesis and hypothesis testing in the clinical trial.
    The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 9

    Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dibenzothiazepines; Humans; Olanzap

2001
Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database.
    The American journal of psychiatry, 2001, Volume: 158, Issue:9

    Topics: Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Clinical Trials as Topic; Dat

2001
Olanzapine induces remarkable weight gain in adolescent patients.
    European child & adolescent psychiatry, 2001, Volume: 10, Issue:3

    Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanzapine; Pirenzepine; Ps

2001
[Importance of blood glucose level when starting antipsychotic treatment].
    Presse medicale (Paris, France : 1983), 2001, Sep-22, Volume: 30, Issue:26

    Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Mid

2001
Olanzapine in pregnancy.
    The Annals of pharmacotherapy, 2001, Volume: 35, Issue:10

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Infant, Newborn; Male; Olanzapine; Pir

2001
Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
    The Journal of clinical psychiatry, 2001, Volume: 62, Issue:9

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Drug Administration Schedu

2001
Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2001, Volume: 46, Issue:8

    Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Intellectual Disability; M

2001
Olanzapine-induced priapism.
    The American journal of psychiatry, 2001, Volume: 158, Issue:12

    Topics: Adult; Benzodiazepines; Erectile Dysfunction; Humans; Male; Olanzapine; Pirenzepine; Priapism; Psych

2001
Acute, progressive akinetic-rigid syndrome induced by neuroleptics in a case of Wilson's disease.
    The Journal of neuropsychiatry and clinical neurosciences, 2001,Fall, Volume: 13, Issue:4

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Hepatolenticular Degeneratio

2001
Body weight gain, insulin, and leptin in olanzapine-treated patients.
    The Journal of clinical psychiatry, 2001, Volume: 62, Issue:11

    Topics: Antipsychotic Agents; Benzodiazepines; Body Weight; Female; Humans; Insulin; Leptin; Male; Metabolic

2001
[Diabetes mellitus induced by olanzapine. A case report].
    Revista medica de Chile, 2001, Volume: 129, Issue:10

    Topics: Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus; Humans; Male; Middle Aged; Olanzapine; Pir

2001
Olanzapine, new-onset diabetes mellitus, and risk for insulin overdose.
    The Journal of clinical psychiatry, 2001, Volume: 62, Issue:12

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 1; Dose-Response Relationship,

2001
Are the atypical antipsychotic drugs antidepressants?
    Journal of clinical psychopharmacology, 2002, Volume: 22, Issue:1

    Topics: Affect; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Depr

2002
Olanzapine for the treatment of monosymptomatic hypochondriacal psychosis.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:2

    Topics: Antipsychotic Agents; Benzodiazepines; Humans; Hypochondriasis; Olanzapine; Pirenzepine; Psychotic D

2002
Eosinophilia associated with olanzapine.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:3

    Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Eosinophilia; Humans; Male;

2002
Olanzapine-induced destabilization of diabetes in the absence of weight gain.
    Acta psychiatrica Scandinavica, 2002, Volume: 105, Issue:3

    Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Diabetes Complications; Diabetes

2002
Weight gain and hyperglycaemia associated with olanzapine.
    The Australian and New Zealand journal of psychiatry, 2002, Volume: 36, Issue:2

    Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Female; Humans; Hyperglycemia; Olanzapine; Pirenz

2002
Clinical and economic outcomes associated with olanzapine for the treatment of psychotic symptoms in a county mental health population.
    Clinical therapeutics, 2002, Volume: 24, Issue:5

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; California; Community Mental Health Services; Cost-Ben

2002
One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics.
    Psychiatric services (Washington, D.C.), 2002, Volume: 53, Issue:7

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Humans; Middle Aged; Olanzapine; Pat

2002
Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study.
    Pharmacopsychiatry, 2002, Volume: 35, Issue:3

    Topics: Antipsychotic Agents; Benzodiazepines; Calorimetry, Indirect; Energy Metabolism; Humans; Male; Middl

2002
Olanzapine and pregnancy.
    Pharmacopsychiatry, 2002, Volume: 35, Issue:3

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Olanzapine; Pirenzepine; Pregnancy; Pr

2002